Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care

Rhea-AI Summary

Medtronic (NYSE: MDT) completed its $550 million acquisition of Scientia Vascular, a Salt Lake City-based neurovascular access device company. Scientia’s guidewires and catheters are designed to improve navigability in complex cerebral anatomy and will integrate with Medtronic’s neurovascular portfolio.

The deal targets enhanced procedural efficiency in stroke and aneurysm care and aligns with Medtronic’s strategy to strengthen core businesses and pursue high-growth opportunities. The transaction is expected to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.

Positive

• Completed acquisition of Scientia Vascular for $550 million plus potential earn-outs
• Enhances Medtronic’s neurovascular portfolio with Scientia’s access guidewires and catheters
• Supports full neurovascular procedural workflow, aiming to improve procedural efficiency
• Aligns with Medtronic focus on high-growth, strategic deals in core businesses
• Acquisition expected to be accretive to adjusted EPS after FY27

Negative

• Acquisition expected to be minimally dilutive to Medtronic adjusted EPS in FY27

News Market Reaction – MDT

-0.16%

-0.16% Session close to close

In the Jun 12 session, MDT declined 0.16%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms the closing of Medtronic’s $550 million acquisition of Scientia Vascular,...

Analysis

This announcement confirms the closing of Medtronic’s $550 million acquisition of Scientia Vascular, adding guidewires and catheters that integrate into its neurovascular portfolio to streamline complex stroke workflows. It follows earlier intent and fits a broader pattern of bolt-on deals in cardiovascular and neuroscience. Investors may monitor how effectively Medtronic scales Scientia’s ~310-person operation, the impact on neurovascular growth, and management’s commentary in future earnings and regulatory filings.

Key Figures

Acquisition value: $550 million Scientia employees: 310 employees Medtronic employees: 95,000+ people +3 more

6 metrics

Acquisition value $550 million Scientia Vascular deal value, subject to customary adjustments

Scientia employees 310 employees Scientia Vascular workforce in Salt Lake City

Medtronic employees 95,000+ people Global Medtronic workforce across more than 150 countries

Countries served 150+ countries Global reach of Medtronic’s operations

Health conditions 70 conditions Number of health conditions Medtronic technologies and therapies address

Patients impacted 2 people every second Medtronic claims its technologies transform lives at this cadence

Previous Acquisition Reports

5 past events · Latest: May 20 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 20	Chronic pain acquisition	Positive	-1.3%	Planned $650M SPR Therapeutics acquisition to expand peripheral nerve stimulation.
Apr 20	CathWorks deal close	Positive	-1.4%	Completion of $585M CathWorks acquisition adding FFRangio coronary physiology platform.
Mar 10	Scientia deal announcement	Positive	-1.6%	Agreement to acquire Scientia Vascular for $550M to enhance neurovascular access tools.
Feb 03	CathWorks intent	Positive	+0.5%	Intent to acquire CathWorks for up to $585M to expand interventional cardiology.
Aug 27	Asset divestiture	Neutral	-0.6%	PaceMate acquisition of Medtronic’s Paceart Optima system and related collaboration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent acquisition headlines for MDT have typically been met with small negative price reactions, with an average move of about -0.89%, suggesting investors often fade M&A announcements even when strategically positive.

Recent Company History

Over the past several months, Medtronic has pursued a steady acquisition strategy to bolster its cardiovascular and neuroscience portfolios. Deals for CathWorks and Scientia Vascular, typically valued in the mid-hundreds of millions, were framed as strategically important yet historically saw modest share-price declines of around -1%. Alongside this, the company reported strong FY26 results with its fastest annual revenue growth in 10 years and raised its dividend. Today’s completion of the Scientia Vascular deal extends that bolt-on M&A trajectory in neurovascular care.

Key Terms

neurovascular, guidewires, catheters, cerebral vasculature, +2 more

6 terms

neurovascular medical

"neurovascular care" and "complex neurovascular conditions. Scientia's portfolio of guidewires"

Neurovascular describes the blood vessels and circulation that supply the brain, spinal cord and other parts of the nervous system, and the medical devices or treatments that protect or repair them. Investors care because disorders of this system—like strokes or aneurysms—drive demand for specialized drugs, devices and procedures; think of it as the plumbing and roads for the brain, where improvements can reduce risk, cut costs, and create market opportunities.

guidewires medical

"Scientia's portfolio of guidewires and catheters can be seamlessly integrated"

Guidewires are thin, flexible metal wires used by doctors as a pathfinder to steer catheters and other instruments through blood vessels or body passages during minimally invasive procedures. Like the lead rope guiding a vehicle through a narrow tunnel, they determine how easily and safely a procedure can be performed; product quality, reliability and regulatory approval affect clinical adoption, procedure outcomes and therefore sales and risk for medical device investors.

catheters medical

"Scientia's portfolio of guidewires and catheters can be seamlessly integrated"

Flexible tubes inserted into the body to deliver fluids, remove liquids, or provide access to blood vessels and organs; they range from simple temporary tubes to specialized devices used in surgeries or long-term care. Investors care because catheter demand, safety records, regulatory approvals, and device improvements directly affect medical-device sales and liability risk—think of them as essential plumbing for healthcare where reliability and regulation drive market value.

cerebral vasculature medical

"Unlike vessels in many other parts of the body, cerebral vasculature is highly complex"

The cerebral vasculature is the network of arteries, veins and tiny vessels that deliver oxygen and nutrients to the brain and remove waste—think of it as the brain’s highway system for blood. It matters to investors because diseases, injuries or treatments that affect these vessels (for example strokes, aneurysms or blood-clotting issues) drive demand for drugs, devices, diagnostics and care, influence regulatory approvals and clinical trial outcomes, and can materially affect a health-related company’s value.

occlusion medical

"attempting to reach the site of an occlusion or aneurysm. Difficult access can delay"

Occlusion is the blocking or closing of a blood vessel or other bodily passage that reduces or stops normal flow—like a kink in a garden hose that prevents water from getting through. For investors, occlusion matters because it is the biological problem many drugs, medical devices and diagnostic tests are designed to treat or detect; its frequency, severity and how well treatments work affect clinical success, regulatory approval, market demand and potential revenue.

aneurysm medical

"attempting to reach the site of an occlusion or aneurysm. Difficult access can delay"

An aneurysm is a weakened area in a blood vessel wall that balloons outward and can leak or rupture, causing serious internal bleeding or organ damage. Investors pay attention because the development, approval, or failure of treatments, diagnostic tools, or medical devices for aneurysms — as well as high-profile ruptures or litigation — can quickly change healthcare costs, patient outcomes and a company's regulatory standing, revenue prospects and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow

GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of Scientia Vascular, a privately-held medical device company in Salt Lake City. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.

Scientia has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow.

"Since its founding, Scientia has been driven by a commitment to improving patients' lives and supporting the physicians who care for them," said Rick Randall, CEO of Scientia. "Joining Medtronic is an exciting next step for our team, as their Mission closely aligns with the values that have guided Scientia from the beginning. With Medtronic's global scale, we look forward to bringing this technology to more physicians and reaching more patients around the world."

"The addition of Scientia's access technologies strengthens our ability to simplify complex neurovascular procedures and support physicians with more seamless solutions," said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, part of the Neuroscience Portfolio at Medtronic. "By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care and enable physicians to treat more patients with greater efficiency and confidence."

In stroke treatment, every second matters. With each second of restricted blood flow, the brain loses millions of brain cells. Today, stroke is the third leading cause of death and leading cause of disability worldwide. 

Unlike vessels in many other parts of the body, cerebral vasculature is highly complex and tortuous, creating significant challenges for physicians attempting to reach the site of an occlusion or aneurysm. Difficult access can delay therapy delivery and impact procedural success.

Scientia's novel access platform is designed to address these challenges by improving navigability through complex anatomy and simplifying neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency.

This acquisition reflects Medtronic's continued focus on strategic deals that strengthen its leadership across core businesses. The company remains committed to pursuing high-growth opportunities that complement its portfolio and enhance value for physicians and hospital partners.

Financial Impact
This acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.

About Scientia Vascular
Scientia is a private company operating in Salt Lake City, with approximately 310 employees. Under founder and chief technology officer John Lippert, the company has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow.

About the Neurovascular Business at Medtronic
Medtronic helped create the neurovascular market – introducing innovations like liquid embolic, stent retrievers, and flow diverters. Today, with products covering multiple conditions and disease states, we work to eliminate the burden of stroke and other neurovascular diseases globally by transforming care, one breakthrough at a time. Together with our partners, including physicians, hospitals, governments and patients, we're expanding into new disease states and stages of care. Our unwavering focus on better outcomes fuels our drive to deliver life-changing therapies and transform the future of care for patients worldwide. For more information, follow Medtronic Neurovascular on LinkedIn.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Justin Paquette	Ingrid Goldberg
Public Relations	Investor Relations
+1-612-271-7935	+1-612-505-2696

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-completes-acquisition-of-scientia-vascular-seamlessly-integrating-access-and-therapeutic-portfolios-for-neurovascular-care-302798654.html

SOURCE Medtronic plc

FAQ

What did Medtronic (MDT) announce about the Scientia Vascular acquisition on June 12, 2026?

Medtronic announced it completed the acquisition of Scientia Vascular, a neurovascular access device company, for $550 million. According to Medtronic, Scientia’s guidewires and catheters will integrate with its neurovascular portfolio to support complex stroke and aneurysm procedures.

How much did Medtronic (MDT) pay to acquire Scientia Vascular?

Medtronic valued the Scientia Vascular acquisition at $550 million, subject to customary adjustments. According to Medtronic, the transaction also includes potential undisclosed earn-out and milestone payments after closing, reflecting expectations for future performance of the acquired neurovascular access platform.

How will the Scientia Vascular acquisition affect Medtronic (MDT) earnings?

The Scientia Vascular acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter. According to Medtronic, this outlook reflects integration of Scientia’s access technologies into its neurovascular business over time.

What products does Scientia Vascular add to Medtronic’s (MDT) neurovascular portfolio?

Scientia Vascular contributes a portfolio of guidewires and catheters for neurovascular access. According to Medtronic, these devices are designed to improve navigability through complex cerebral anatomy, simplify procedures, and integrate with its existing neurovascular therapies across the full procedural workflow.

Why is Medtronic (MDT) acquiring Scientia Vascular for its neurovascular business?

Medtronic is acquiring Scientia Vascular to strengthen its neurovascular access capabilities and support complex stroke procedures. According to Medtronic, combining the highly complementary technologies should create a more integrated platform, aiming to enhance procedural efficiency and support high-growth opportunities in neurovascular care.

How many employees does Scientia Vascular have before joining Medtronic (MDT)?

Scientia Vascular operates in Salt Lake City with approximately 310 employees prior to its acquisition. According to Medtronic, the company was founded under chief technology officer John Lippert and focuses on access products for complex neurovascular conditions, including stroke and aneurysm interventions.

What does the Scientia Vascular acquisition mean for Medtronic (MDT) stroke treatment strategy?

The acquisition adds an access platform aimed at faster, more reliable navigation to stroke and aneurysm sites. According to Medtronic, improving access in complex cerebral vasculature can support procedural success, aligning with its broader goal to reduce the global burden of stroke.